Investigating how immune therapies affect hip osteoarthritis and inflammatory arthritis
Evaluating the relationship between immune checkpoint inhibitors and osteoarthritis
This study is looking at how having hip osteoarthritis might affect cancer patients who are being treated with immune checkpoint inhibitors, specifically whether those with hip OA are more likely to develop inflammatory arthritis and if their symptoms get worse faster than others.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10762461 on NIH RePORTER |
What this research studies
This research aims to explore the connection between hip osteoarthritis (OA) and the development of inflammatory arthritis (IA) in patients receiving immune checkpoint inhibitors (ICIs) for cancer treatment. It will assess whether patients with existing hip OA are at a higher risk of developing IA due to ICIs and whether their condition worsens more rapidly compared to other cancer patients. By analyzing data from patients already treated with ICIs and utilizing CT imaging, the study seeks to identify risk factors for IA and understand how joint abnormalities may trigger systemic inflammation. This knowledge could lead to better patient monitoring and preventive strategies for those undergoing ICI therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research include cancer patients with preexisting hip osteoarthritis who are being treated with immune checkpoint inhibitors.
Not a fit: Patients without hip osteoarthritis or those not receiving immune checkpoint inhibitors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could help identify patients at risk for inflammatory arthritis, leading to improved management and treatment strategies for those receiving immune therapies.
How similar studies have performed: While the relationship between immune therapies and joint conditions is being explored, this specific investigation into hip OA as a risk factor for IA due to ICIs is relatively novel.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Cappelli, Laura Christine — Johns Hopkins University
- Study coordinator: Cappelli, Laura Christine
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.